Novartis AG (NVS) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Novartis AG

    NYSE: NVS · Real-Time Price · USD
    128.65
    -1.08 (-0.83%)
    At close: Sep 08, 2025, 3:59 PM
    128.63
    -0.02%
    Pre-market: Sep 09, 2025, 06:02 AM EDT

    Novartis Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 11.94B 8.57B 6.96B 24.02B
    Depreciation & Amortization
    		 6.07B 8.28B 7.18B 6.11B
    Stock-Based Compensation
    		 1.04B 865M 791M 700M
    Other Working Capital
    		 555M 1.2B 464M 570M
    Other Non-Cash Items
    		 -2.43B -3.44B -1.14B -18.16B
    Deferred Income Tax
    		 1.7B 551M 1.42B 2.12B
    Change in Working Capital
    		 -706M -369M -1B 241M
    Operating Cash Flow
    		 17.62B 14.46B 14.24B 15.07B
    Capital Expenditures
    		 -3.81B -2.75B -2.67B -2.97B
    Cash Acquisitions
    		 -3.83B -3.57B -903M 20.1B
    Purchase of Investments
    		 -3.65B -758M -34.82B -16.59B
    Sales Maturities Of Investments
    		 3.7B 11.6B 39.49B 2.74B
    Other Investing Acitivies
    		 -2.38B 1.08B 368M 931M
    Investing Cash Flow
    		 -7.51B 5.6B 1.47B 4.21B
    Debt Repayment
    		 4.39B -1.68B -2.58B -2.44B
    Common Stock Repurchased
    		 -8.33B -8.72B -10.65B -3.06B
    Dividend Paid
    		 -7.62B -7.25B -7.51B -7.37B
    Other Financial Acitivies
    		 -177M 3.37B 181M -3.4B
    Financial Cash Flow
    		 -11.74B -14.28B -20.56B -16.26B
    Net Cash Flow
    		 -1.93B 5.88B -4.89B 2.75B
    Free Cash Flow
    		 13.8B 11.71B 11.56B 12.1B

    Add to Watchlist